vTv Therapeutics Stock Price, News & Analysis (NASDAQ:VTVT)

$4.65 0.01 (0.22 %)
(As of 12/11/2017 06:19 AM ET)
Previous Close$4.64
Today's Range$4.56 - $4.89
52-Week Range$3.57 - $8.09
Volume28,800 shs
Average Volume31,578 shs
Market Capitalization$152.58 million
P/E RatioN/A
Dividend YieldN/A
Beta0.64

About vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics logovTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300

Debt

Debt-to-Equity RatioN/A
Current Ratio1.76%
Quick Ratio1.76%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$630,000.00
Price / Sales242.17
Cash FlowN/A
Price / CashN/A
Book Value($2.75) per share
Price / Book-1.69

Profitability

Trailing EPS($1.65)
Net Income$-16,350,000.00
Net Margins-16,544.79%
Return on EquityN/A
Return on Assets-39.06%

Miscellaneous

Employees51
Outstanding Shares32,810,000

vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) posted its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.02. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.19 million. View vTv Therapeutics' Earnings History.

When will vTv Therapeutics make its next earnings announcement?

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for vTv Therapeutics.

Where is vTv Therapeutics' stock going? Where will vTv Therapeutics' stock price be in 2017?

5 equities research analysts have issued 1 year price objectives for vTv Therapeutics' stock. Their predictions range from $12.00 to $24.00. On average, they expect vTv Therapeutics' stock price to reach $16.00 in the next year. View Analyst Ratings for vTv Therapeutics.

Who are some of vTv Therapeutics' key competitors?

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the folowing people:

  • Jeffrey B Kindler, Executive Chairman of the Board (Age 61)
  • Stephen L. Holcombe, President, Chief Executive Officer (Age 59)
  • Rudy C. Howard CPA, Chief Financial Officer, Executive Vice President (Age 58)
  • Larry Douglas Altstiel M.D. Ph.D., Chief Medical Officer (Age 66)
  • Steven M. Cohen, Director (Age 52)
  • Paul M. Meister, Director (Age 64)
  • Paul G. Savas, Director (Age 53)
  • Howard L. Weiner, Director
  • John A. Fry, Independent Director (Age 55)

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Who owns vTv Therapeutics stock?

vTv Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include MACANDREWS & FORBES INC. (79.70%), Ameriprise Financial Inc. (0.53%) and JPMorgan Chase & Co. (0.25%). Company insiders that own vTv Therapeutics stock include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

Who sold vTv Therapeutics stock? Who is selling vTv Therapeutics stock?

vTv Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc.. View Insider Buying and Selling for vTv Therapeutics.

Who bought vTv Therapeutics stock? Who is buying vTv Therapeutics stock?

vTv Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have bought vTv Therapeutics stock in the last two years include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.

How do I buy vTv Therapeutics stock?

Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of vTv Therapeutics stock can currently be purchased for approximately $4.65.

How big of a company is vTv Therapeutics?

vTv Therapeutics has a market capitalization of $152.58 million and generates $630,000.00 in revenue each year. The biotechnology company earns $-16,350,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. vTv Therapeutics employs 51 workers across the globe.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]


MarketBeat Community Rating for vTv Therapeutics (VTVT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

vTv Therapeutics (NASDAQ:VTVT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.803.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00$16.50$17.40
Price Target Upside: 173.04% upside173.04% upside289.15% upside221.63% upside

vTv Therapeutics (NASDAQ:VTVT) Consensus Price Target History

Price Target History for vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ:VTVT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017CitigroupReiterated RatingaddN/AView Rating Details
11/3/2017Stifel NicolausReiterated RatingBuy$12.00N/AView Rating Details
8/4/2017Canaccord GenuityReiterated RatingBuy$15.00LowView Rating Details
8/4/2017HC WainwrightSet Price TargetBuy$13.00LowView Rating Details
3/30/2017Piper Jaffray CompaniesReiterated RatingOverweight$24.00LowView Rating Details
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

vTv Therapeutics (NASDAQ:VTVT) Earnings History and Estimates Chart

Earnings by Quarter for vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ VTVT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018        
8/2/2017Q2 2017($0.43)($0.41)$0.19 million$0.01 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.44)($0.44)$0.20 million$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.54)($0.42)$0.38 millionViewN/AView Earnings Details
3/1/2016Q4($0.47)($0.35)$0.03 million$0.23 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

vTv Therapeutics (NASDAQ:VTVT) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.65 EPS
Next Year EPS Consensus Estimate: $-1.49 EPS

Dividends

Dividend History for vTv Therapeutics (NASDAQ:VTVT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

vTv Therapeutics (NASDAQ VTVT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 10.42%
Insider Trades by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Institutional Ownership by Quarter for vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ VTVT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/7/2017Paul G SavasDirectorBuy15,000$4.56$68,400.00View SEC Filing  
8/22/2017Ronald O PerelmanMajor ShareholderBuy20,000$4.57$91,400.00View SEC Filing  
8/16/2017Ronald O PerelmanMajor ShareholderBuy10,000$4.97$49,700.00View SEC Filing  
8/15/2017Ronald O PerelmanMajor ShareholderBuy50,000$4.72$236,000.00View SEC Filing  
8/11/2017Ronald O PerelmanMajor ShareholderBuy85,000$4.13$351,050.00View SEC Filing  
5/15/2017Paul G SavasDirectorBuy3,000$5.18$15,540.00View SEC Filing  
3/31/2017Paul G SavasDirectorBuy10,000$6.50$65,000.00View SEC Filing  
5/27/2016Paul G SavasDirectorBuy6,000$5.67$34,020.00View SEC Filing  
5/24/2016Paul G SavasDirectorBuy1,259$5.26$6,622.34View SEC Filing  
4/8/2016Ronald O PerelmanMajor ShareholderBuy10,000$4.99$49,900.00View SEC Filing  
4/5/2016Ronald O PerelmanMajor ShareholderBuy400,000$5.20$2,080,000.00View SEC Filing  
3/28/2016Paul G SavasDirectorBuy10,000$5.35$53,500.00View SEC Filing  
3/24/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.64$56,400.00View SEC Filing  
3/7/2016Paul G SavasDirectorBuy15,000$5.82$87,300.00View SEC Filing  
2/12/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.83$58,300.00View SEC Filing  
2/5/2016Ronald O PerelmanMajor ShareholderBuy10,000$6.43$64,300.00View SEC Filing  
2/4/2016Ronald O PerelmanMajor ShareholderBuy20,000$6.05$121,000.00View SEC Filing  
1/13/2016Ronald O PerelmanMajor ShareholderBuy15,000$6.41$96,150.00View SEC Filing  
12/18/2015Ronald O PerelmanMajor ShareholderBuy15,000$6.40$96,000.00View SEC Filing  
12/15/2015Noel Joseph SpiegelDirectorBuy5,710$6.20$35,402.00View SEC Filing  
10/2/2015Ronald O PerelmanMajor ShareholderBuy30,000$6.26$187,800.00View SEC Filing  
9/28/2015Ronald O PerelmanMajor ShareholderBuy40,000$6.04$241,600.00View SEC Filing  
9/25/2015Paul G SavasDirectorBuy5,000$6.62$33,100.00View SEC Filing  
9/22/2015Ronald O PerelmanMajor ShareholderBuy24,000$6.82$163,680.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

vTv Therapeutics (NASDAQ VTVT) News Headlines

Source:
DateHeadline
Insider Buying: vTv Therapeutics Inc. (VTVT) Director Purchases 15,000 Shares of StockInsider Buying: vTv Therapeutics Inc. (VTVT) Director Purchases 15,000 Shares of Stock
www.americanbankingnews.com - December 7 at 9:02 PM
vTv Therapeutics Inc. (VTVT) Given Consensus Recommendation of "Buy" by AnalystsvTv Therapeutics Inc. (VTVT) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 3 at 3:44 AM
vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s DiseasevTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease
finance.yahoo.com - November 13 at 11:06 AM
vTv Therapeutics Inc. (VTVT) Earns "add" Rating from Citigroup Inc.vTv Therapeutics Inc. (VTVT) Earns "add" Rating from Citigroup Inc.
www.americanbankingnews.com - November 8 at 7:44 PM
ETFs with exposure to vTv Therapeutics, Inc. : November 6, 2017ETFs with exposure to vTv Therapeutics, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 1:25 PM
Stifel Nicolaus Reiterates Buy Rating for vTv Therapeutics Inc. (VTVT)Stifel Nicolaus Reiterates Buy Rating for vTv Therapeutics Inc. (VTVT)
www.americanbankingnews.com - November 4 at 6:42 PM
vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 6:20 AM
vTv Therapeutics Reports Third Quarter 2017 Financial and Operational ResultsvTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results
finance.yahoo.com - November 2 at 11:14 AM
vTv Therapeutics Reports Third Quarter 2017 Financial and Operational ResultsvTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results
finance.yahoo.com - November 2 at 11:14 AM
vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)
finance.yahoo.com - October 30 at 8:28 AM
vTv Therapeutics (VTVT) versus Its Peers Critical SurveyvTv Therapeutics (VTVT) versus Its Peers Critical Survey
www.americanbankingnews.com - October 26 at 1:16 AM
vTv Therapeutics Inc. (VTVT) Set to Announce Earnings on TuesdayvTv Therapeutics Inc. (VTVT) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 24 at 5:46 AM
ETFs with exposure to vTv Therapeutics, Inc. : October 11, 2017ETFs with exposure to vTv Therapeutics, Inc. : October 11, 2017
finance.yahoo.com - October 12 at 9:58 AM
Why vTv Therapeutics (VTVT) Could Be Positioned for a SurgeWhy vTv Therapeutics (VTVT) Could Be Positioned for a Surge
finance.yahoo.com - October 12 at 9:58 AM
vTv Therapeutics Inc. (VTVT) Downgraded by Zacks Investment Research to "Hold"vTv Therapeutics Inc. (VTVT) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - October 5 at 6:58 PM
Comparing BIOVERATIV INC (BIVV) & vTv Therapeutics (VTVT)Comparing BIOVERATIV INC (BIVV) & vTv Therapeutics (VTVT)
www.americanbankingnews.com - September 22 at 12:22 AM
Contrasting vTv Therapeutics (VTVT) & Aradigm Corporation (ARDM)Contrasting vTv Therapeutics (VTVT) & Aradigm Corporation (ARDM)
www.americanbankingnews.com - September 18 at 6:10 AM
 Analysts Expect vTv Therapeutics Inc. (VTVT) Will Post Quarterly Sales of $200,000.00 Analysts Expect vTv Therapeutics Inc. (VTVT) Will Post Quarterly Sales of $200,000.00
www.americanbankingnews.com - September 14 at 9:59 AM
-$0.42 EPS Expected for vTv Therapeutics Inc. (VTVT) This Quarter-$0.42 EPS Expected for vTv Therapeutics Inc. (VTVT) This Quarter
www.americanbankingnews.com - September 12 at 8:26 AM
vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of ...vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of ...
www.businesswire.com - September 7 at 11:06 AM
vTv Therapeutics snags funding for study of its diabetes-targeting drugvTv Therapeutics snags funding for study of its diabetes-targeting drug
finance.yahoo.com - September 7 at 11:06 AM
vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of DiabetesvTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of Diabetes
finance.yahoo.com - September 7 at 11:05 AM
JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 DiabetesJDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes
finance.yahoo.com - September 6 at 10:09 AM
ETFs with exposure to vTv Therapeutics, Inc. : September 1, 2017ETFs with exposure to vTv Therapeutics, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 10:59 AM
$200,000.00 in Sales Expected for vTv Therapeutics Inc. (VTVT) This Quarter$200,000.00 in Sales Expected for vTv Therapeutics Inc. (VTVT) This Quarter
www.americanbankingnews.com - August 26 at 3:22 AM
vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 12:30 PM
vTv Therapeutics Inc. (VTVT) Major Shareholder Buys $91,400.00 in StockvTv Therapeutics Inc. (VTVT) Major Shareholder Buys $91,400.00 in Stock
www.americanbankingnews.com - August 24 at 7:58 PM
vTv Therapeutics Inc. (VTVT) Major Shareholder Ronald O. Perelman Purchases 10,000 SharesvTv Therapeutics Inc. (VTVT) Major Shareholder Ronald O. Perelman Purchases 10,000 Shares
www.americanbankingnews.com - August 16 at 9:34 PM
Insider Buying: vTv Therapeutics Inc. (VTVT) Major Shareholder Purchases 50,000 Shares of StockInsider Buying: vTv Therapeutics Inc. (VTVT) Major Shareholder Purchases 50,000 Shares of Stock
www.americanbankingnews.com - August 15 at 7:40 PM
Insider Buying: vTv Therapeutics Inc. (VTVT) Major Shareholder Acquires 85,000 Shares of StockInsider Buying: vTv Therapeutics Inc. (VTVT) Major Shareholder Acquires 85,000 Shares of Stock
www.americanbankingnews.com - August 14 at 11:10 PM
 Analysts Expect vTv Therapeutics Inc. (VTVT) Will Announce Quarterly Sales of $200,000.00 Analysts Expect vTv Therapeutics Inc. (VTVT) Will Announce Quarterly Sales of $200,000.00
www.americanbankingnews.com - August 8 at 7:44 AM
vTv Therapeutics Inc. (NASDAQ:VTVT) PT Set at $13.00 by HC WainwrightvTv Therapeutics Inc. (NASDAQ:VTVT) PT Set at $13.00 by HC Wainwright
www.americanbankingnews.com - August 6 at 10:26 PM
-$0.44 EPS Expected for vTv Therapeutics Inc. (VTVT) This Quarter-$0.44 EPS Expected for vTv Therapeutics Inc. (VTVT) This Quarter
www.americanbankingnews.com - August 6 at 12:28 PM
vTv Therapeutics Inc. (VTVT) Announces  Earnings ResultsvTv Therapeutics Inc. (VTVT) Announces Earnings Results
www.americanbankingnews.com - August 4 at 3:52 PM
vTv Therapeutics Inc. (VTVT) Earns "Buy" Rating from Canaccord GenuityvTv Therapeutics Inc. (VTVT) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - August 4 at 1:48 PM
vTv Therapeutics Reports Second Quarter 2017 Financial and Operational ResultsvTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results
finance.yahoo.com - August 3 at 8:48 AM
VTv Therapeutics reports 2Q lossVTv Therapeutics reports 2Q loss
finance.yahoo.com - August 3 at 8:47 AM
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using AzeliragonvTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon
finance.yahoo.com - August 3 at 8:47 AM
Were not going to be taken off — vTv Therapeutics CEO responds to NASDAQs delisting warning'We're not going to be taken off' — vTv Therapeutics CEO responds to NASDAQ's delisting warning
finance.yahoo.com - July 21 at 8:32 AM
vTv Therapeutics to Present Two Posters at the 2017 Alzheimers Association International ConferencevTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference
finance.yahoo.com - July 14 at 9:52 AM
Triad pharma companys stock could be delistedTriad pharma company's stock could be delisted
www.bizjournals.com - July 6 at 10:18 PM
VTV THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsVTV THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 29 at 10:09 AM
vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent HighlightsvTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
us.rd.yahoo.com - February 28 at 11:07 AM
VTV THERAPEUTICS INC. Files SEC form 10-K, Annual ReportVTV THERAPEUTICS INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - February 25 at 4:20 AM
vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 DiabetesvTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes
us.rd.yahoo.com - December 15 at 7:13 AM
4:33 pm vTv Therapeutics announces positve data from its Phase 2 study evaluating TTP273 for the treatment of Type 2 diabetes; Oral small molecule GLP-1 receptor agonist met primary endpoint4:33 pm vTv Therapeutics announces 'positve' data from its Phase 2 study evaluating TTP273 for the treatment of Type 2 diabetes; Oral small molecule GLP-1 receptor agonist met primary endpoint
us.rd.yahoo.com - December 15 at 7:13 AM
vTv Therapeutics (VTVT) to Present New Small Molecule Drug Candidate Data as PD Treatment at Upcoming ConferencevTv Therapeutics (VTVT) to Present New Small Molecule Drug Candidate Data as PD Treatment at Upcoming Conference
www.streetinsider.com - November 16 at 12:14 PM
VTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhVTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
biz.yahoo.com - November 2 at 8:48 PM
VTV THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct FinancialVTV THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
biz.yahoo.com - October 31 at 8:48 AM

SEC Filings

vTv Therapeutics (NASDAQ:VTVT) SEC Filings

DateFilerForm TypeView
12/07/2017
6:47 PM
SAVAS PAUL G (Reporting)
vTv Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/07/2017
4:17 PM
PERELMAN RONALD O (Reporting)
vTv Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/07/2017
3:39 PM
MacAndrews & Forbes Inc. (Filed by)
vTv Therapeutics (Subject)
Form SC 13D/A
View Filing

Social Media

Financials

vTv Therapeutics (NASDAQ:VTVT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

vTv Therapeutics (NASDAQ VTVT) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.